Treats Parkinson’s disease (PD). Sold as Azilect. Every FDA application for this active ingredient: 1 branded and 13 generic.
As of Nov 16, 2026, FDA lists 14 applications for Rasagiline Mesylate (sold as Azilect), first approved May 16, 2006, with 2 new uses approved and 0 published complete response letters.
| Rasagiline Mesylate | Part D | $23.8M | -16% | 31,475 |
| Azilect | Part D | $1.1M | -22% | 102 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Relative Bioavailability Study of HNC364 Injectable SuspensionParkinson's Disease (PD) · Guangzhou Henovcom Bioscience Co. Ltd. | Phase 1 | Active, not recruiting | Jan 29, 2025 |
| May 16, 2006 | AzilectNDA 21641 · New molecular entity | Teva | 13 | Marketed |
| Jul 1, 2013 | Rasagiline MesylateANDA 201823 | Watson Labs Inc | 0 | Discontinued |
| Sep 12, 2013 | Rasagiline MesylateANDA 201950 | Apotex Inc | 1 | Discontinued |
| Mar 15, 2016 | Rasagiline MesylateANDA 201970 | Orbion Pharms | 3 | Marketed |
| May 15, 2017 | Rasagiline MesylateANDA 201971 | Aurobindo Pharma USA | 2 | Marketed |
| Oct 30, 2017 | Rasagiline MesylateANDA 201889 | Alkem Labs Ltd | 2 | Marketed |
| Jul 27, 2018 | Rasagiline MesylateANDA 201892 | Chartwell Rx | 1 | Marketed |
| Mar 29, 2019 | Rasagiline MesylateANDA 207004 | Micro Labs | 1 | Marketed |
| Oct 4, 2019 | Rasagiline MesylateANDA 206153 | Regcon Holdings | 1 | Marketed |
| Nov 18, 2021 | Rasagiline MesylateANDA 201942 | Carnegie | 0 | Marketed |
| Apr 9, 2024 | Rasagiline MesylateANDA 218163 | Rising | 0 | Marketed |
| Jun 28, 2024 | Rasagiline MesylateANDA 208866 | Macleods Pharms | 0 | Marketed |
| May 5, 2025 | Rasagiline MesylateANDA 210150 | Torrent | 0 | Marketed |
| — | Rasagiline MesylateANDA 201899 | Alkem Labs Ltd | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA